Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000664487 | SCV000788453 | likely pathogenic | Glucose-6-phosphate transport defect | 2018-02-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000664487 | SCV002243900 | pathogenic | Glucose-6-phosphate transport defect | 2021-10-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 549913). Disruption of this splice site has been observed in individual(s) with SLC37A4-related conditions (PMID: 9675154, 10323254). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 3 of the SLC37A4 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SLC37A4 are known to be pathogenic (PMID: 9758626, 10940311). |
Baylor Genetics | RCV000664487 | SCV004202464 | likely pathogenic | Glucose-6-phosphate transport defect | 2023-05-11 | criteria provided, single submitter | clinical testing |